Dinaciclib induces anaphase catastrophe in lung cancer cells via inhibition of cyclin-dependent kinases 1 and 2

Alexey Danilov, Shanhu Hu, Bernardo Orr, Kristina Godek, Lisa Maria Mustachio, David Sekula, Xi Liu, Masanori Kawakami, Faye M. Johnson, Duane A. Compton, Sarah J. Freemantle, Ethan Dmitrovsky

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Despite advances in targeted therapy, lung cancer remains the most common cause of cancer-related mortality in the United States. Chromosomal instability is a prominent feature in lung cancer and, because it rarely occurs in normal cells, it represents a potential therapeutic target. Our prior work discovered that lung cancer cells undergo anaphase catastrophe in response to inhibition of cyclin-dependent kinase 2 (CDK2), followed by apoptosis and reduced growth. In this study, the effects and mechanisms of the multi-CDK inhibitor dinaciclib on lung cancer cells were investigated. We sought to determine the specificity of CDK-dependent induction of anaphase catastrophe. Live cell imaging provided direct evidence that dinaciclib caused multipolar cell divisions resulting in extensive chromosome missegregation. Genetic knockdown of dinaciclib CDK targets revealed that repression of CDK2 and CDK1, but not CDK5 or CDK9, triggered anaphase catastrophe in lung cancer cells. Overexpression of CP110, which is a mediator of CDK2 inhibitor-induced anaphase catastrophe (and a CDK1 and 2 phosphorylation substrate), antagonized anaphase catastrophe and apoptosis following dinaciclib treatment. Consistent with our previous findings, acquisition of activated KRAS sensitized lung cancer cells to dinaciclib-mediated anaphase catastrophe and cell death. Combining dinaciclib with the mitotic inhibitor taxol augmented anaphase catastrophe induction and reduced cell viability of lung cancer cells. Thus, the multi-CDK inhibitor dinaciclib causes anaphase catastrophe in lung cancer cells and should be investigated as a potential therapeutic for wild-type and KRAS-mutant lung cancer, individually or in combination with taxanes.

Original languageEnglish (US)
Pages (from-to)2758-2766
Number of pages9
JournalMolecular Cancer Therapeutics
Volume15
Issue number11
DOIs
StatePublished - Nov 1 2016
Externally publishedYes

Fingerprint

CDC2 Protein Kinase
Cyclin-Dependent Kinase 2
Anaphase
Lung Neoplasms
Apoptosis
dinaciclib
Taxoids
Chromosomal Instability
Paclitaxel
Cell Division
Cell Survival
Cell Death
Therapeutics
Chromosomes
Phosphorylation

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Dinaciclib induces anaphase catastrophe in lung cancer cells via inhibition of cyclin-dependent kinases 1 and 2. / Danilov, Alexey; Hu, Shanhu; Orr, Bernardo; Godek, Kristina; Mustachio, Lisa Maria; Sekula, David; Liu, Xi; Kawakami, Masanori; Johnson, Faye M.; Compton, Duane A.; Freemantle, Sarah J.; Dmitrovsky, Ethan.

In: Molecular Cancer Therapeutics, Vol. 15, No. 11, 01.11.2016, p. 2758-2766.

Research output: Contribution to journalArticle

Danilov, A, Hu, S, Orr, B, Godek, K, Mustachio, LM, Sekula, D, Liu, X, Kawakami, M, Johnson, FM, Compton, DA, Freemantle, SJ & Dmitrovsky, E 2016, 'Dinaciclib induces anaphase catastrophe in lung cancer cells via inhibition of cyclin-dependent kinases 1 and 2', Molecular Cancer Therapeutics, vol. 15, no. 11, pp. 2758-2766. https://doi.org/10.1158/1535-7163.MCT-16-0127
Danilov, Alexey ; Hu, Shanhu ; Orr, Bernardo ; Godek, Kristina ; Mustachio, Lisa Maria ; Sekula, David ; Liu, Xi ; Kawakami, Masanori ; Johnson, Faye M. ; Compton, Duane A. ; Freemantle, Sarah J. ; Dmitrovsky, Ethan. / Dinaciclib induces anaphase catastrophe in lung cancer cells via inhibition of cyclin-dependent kinases 1 and 2. In: Molecular Cancer Therapeutics. 2016 ; Vol. 15, No. 11. pp. 2758-2766.
@article{8d354cf3357045ebb4392c6f7b5354bb,
title = "Dinaciclib induces anaphase catastrophe in lung cancer cells via inhibition of cyclin-dependent kinases 1 and 2",
abstract = "Despite advances in targeted therapy, lung cancer remains the most common cause of cancer-related mortality in the United States. Chromosomal instability is a prominent feature in lung cancer and, because it rarely occurs in normal cells, it represents a potential therapeutic target. Our prior work discovered that lung cancer cells undergo anaphase catastrophe in response to inhibition of cyclin-dependent kinase 2 (CDK2), followed by apoptosis and reduced growth. In this study, the effects and mechanisms of the multi-CDK inhibitor dinaciclib on lung cancer cells were investigated. We sought to determine the specificity of CDK-dependent induction of anaphase catastrophe. Live cell imaging provided direct evidence that dinaciclib caused multipolar cell divisions resulting in extensive chromosome missegregation. Genetic knockdown of dinaciclib CDK targets revealed that repression of CDK2 and CDK1, but not CDK5 or CDK9, triggered anaphase catastrophe in lung cancer cells. Overexpression of CP110, which is a mediator of CDK2 inhibitor-induced anaphase catastrophe (and a CDK1 and 2 phosphorylation substrate), antagonized anaphase catastrophe and apoptosis following dinaciclib treatment. Consistent with our previous findings, acquisition of activated KRAS sensitized lung cancer cells to dinaciclib-mediated anaphase catastrophe and cell death. Combining dinaciclib with the mitotic inhibitor taxol augmented anaphase catastrophe induction and reduced cell viability of lung cancer cells. Thus, the multi-CDK inhibitor dinaciclib causes anaphase catastrophe in lung cancer cells and should be investigated as a potential therapeutic for wild-type and KRAS-mutant lung cancer, individually or in combination with taxanes.",
author = "Alexey Danilov and Shanhu Hu and Bernardo Orr and Kristina Godek and Mustachio, {Lisa Maria} and David Sekula and Xi Liu and Masanori Kawakami and Johnson, {Faye M.} and Compton, {Duane A.} and Freemantle, {Sarah J.} and Ethan Dmitrovsky",
year = "2016",
month = "11",
day = "1",
doi = "10.1158/1535-7163.MCT-16-0127",
language = "English (US)",
volume = "15",
pages = "2758--2766",
journal = "Molecular Cancer Therapeutics",
issn = "1535-7163",
publisher = "American Association for Cancer Research Inc.",
number = "11",

}

TY - JOUR

T1 - Dinaciclib induces anaphase catastrophe in lung cancer cells via inhibition of cyclin-dependent kinases 1 and 2

AU - Danilov, Alexey

AU - Hu, Shanhu

AU - Orr, Bernardo

AU - Godek, Kristina

AU - Mustachio, Lisa Maria

AU - Sekula, David

AU - Liu, Xi

AU - Kawakami, Masanori

AU - Johnson, Faye M.

AU - Compton, Duane A.

AU - Freemantle, Sarah J.

AU - Dmitrovsky, Ethan

PY - 2016/11/1

Y1 - 2016/11/1

N2 - Despite advances in targeted therapy, lung cancer remains the most common cause of cancer-related mortality in the United States. Chromosomal instability is a prominent feature in lung cancer and, because it rarely occurs in normal cells, it represents a potential therapeutic target. Our prior work discovered that lung cancer cells undergo anaphase catastrophe in response to inhibition of cyclin-dependent kinase 2 (CDK2), followed by apoptosis and reduced growth. In this study, the effects and mechanisms of the multi-CDK inhibitor dinaciclib on lung cancer cells were investigated. We sought to determine the specificity of CDK-dependent induction of anaphase catastrophe. Live cell imaging provided direct evidence that dinaciclib caused multipolar cell divisions resulting in extensive chromosome missegregation. Genetic knockdown of dinaciclib CDK targets revealed that repression of CDK2 and CDK1, but not CDK5 or CDK9, triggered anaphase catastrophe in lung cancer cells. Overexpression of CP110, which is a mediator of CDK2 inhibitor-induced anaphase catastrophe (and a CDK1 and 2 phosphorylation substrate), antagonized anaphase catastrophe and apoptosis following dinaciclib treatment. Consistent with our previous findings, acquisition of activated KRAS sensitized lung cancer cells to dinaciclib-mediated anaphase catastrophe and cell death. Combining dinaciclib with the mitotic inhibitor taxol augmented anaphase catastrophe induction and reduced cell viability of lung cancer cells. Thus, the multi-CDK inhibitor dinaciclib causes anaphase catastrophe in lung cancer cells and should be investigated as a potential therapeutic for wild-type and KRAS-mutant lung cancer, individually or in combination with taxanes.

AB - Despite advances in targeted therapy, lung cancer remains the most common cause of cancer-related mortality in the United States. Chromosomal instability is a prominent feature in lung cancer and, because it rarely occurs in normal cells, it represents a potential therapeutic target. Our prior work discovered that lung cancer cells undergo anaphase catastrophe in response to inhibition of cyclin-dependent kinase 2 (CDK2), followed by apoptosis and reduced growth. In this study, the effects and mechanisms of the multi-CDK inhibitor dinaciclib on lung cancer cells were investigated. We sought to determine the specificity of CDK-dependent induction of anaphase catastrophe. Live cell imaging provided direct evidence that dinaciclib caused multipolar cell divisions resulting in extensive chromosome missegregation. Genetic knockdown of dinaciclib CDK targets revealed that repression of CDK2 and CDK1, but not CDK5 or CDK9, triggered anaphase catastrophe in lung cancer cells. Overexpression of CP110, which is a mediator of CDK2 inhibitor-induced anaphase catastrophe (and a CDK1 and 2 phosphorylation substrate), antagonized anaphase catastrophe and apoptosis following dinaciclib treatment. Consistent with our previous findings, acquisition of activated KRAS sensitized lung cancer cells to dinaciclib-mediated anaphase catastrophe and cell death. Combining dinaciclib with the mitotic inhibitor taxol augmented anaphase catastrophe induction and reduced cell viability of lung cancer cells. Thus, the multi-CDK inhibitor dinaciclib causes anaphase catastrophe in lung cancer cells and should be investigated as a potential therapeutic for wild-type and KRAS-mutant lung cancer, individually or in combination with taxanes.

UR - http://www.scopus.com/inward/record.url?scp=84995463493&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84995463493&partnerID=8YFLogxK

U2 - 10.1158/1535-7163.MCT-16-0127

DO - 10.1158/1535-7163.MCT-16-0127

M3 - Article

C2 - 27550941

AN - SCOPUS:84995463493

VL - 15

SP - 2758

EP - 2766

JO - Molecular Cancer Therapeutics

JF - Molecular Cancer Therapeutics

SN - 1535-7163

IS - 11

ER -